Navigation Links
Cybrexa Therapeutics Secures $6 Million in Series B Financing
Date:6/15/2017

Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has secured a Series B round of financing in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, Connecticut Innovations, and a group of private investors participated in the round.

The Series B funding will enable Cybrexa to complete the build-out of its facilities and continue the development its tumor-localizing DNA repair inhibitors, which they refer to as Tumor Specific Drugs (TSDs).

Cybrexa was founded by successful entrepreneurs Per Hellsund, Kevin Didden and Kevin Rakin, who most recently built and successfully exited Cyvek, Inc. Hellsund serves as the President and CEO, and Didden and Rakin serve as board members. Additional members of the founding team include Ranjit Bindra, M.D., Ph.D., and Peter Glazer, M.D., Ph.D., from the Yale School of Medicine. Bindra and Glazer are both physician-scientists and world-renowned experts in DNA repair. Their work has been published in numerous high-impact journals, including Science, Nature, and Science Translational Medicine.

Hellsund commented, “We are very pleased to have closed our Series B financing. Our approach has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of TSDs can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.”

About Cybrexa:
Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. The Company is led by an experienced team of researchers and business executives who have developed and commercialized technologies, launched products, driven sales, negotiated partnerships, and led a number of companies from start up to liquidity events.

For more information about Cybrexa, please call 203-717-2731 or visit us on the web at http://www.cybrexa.com

Read the full story at http://www.prweb.com/releases/2017/06/prweb14424114.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Novira Therapeutics Completes $25 Million Series A Financing
3. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
4. Aratana Therapeutics Adds To Drug Development Team
5. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
6. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
7. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
8. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2018)... ... August 28, 2018 , ... Nanovis , an innovative ... completion of a $5.5 million funding round managed by Commenda Securities. Key investors ... and Ellipsis Ventures. , “Our investment in Nanovis is consistent with our mission ...
(Date:8/29/2018)... ... August 28, 2018 , ... CEO and ... a safety study performed on an allogeneic (donor derived) stem cell product for ... (NAVRMA) conference in September. He is also the organizer of Breakout Session ...
(Date:8/26/2018)... ... August 23, 2018 , ... LabRoots , the ... around the world, will host the 4th Annual Microbiology and Immunology Virtual Event ... disciplines, encompassing various research areas including medicine, agriculture, and space. , During ...
(Date:8/23/2018)... , ... August 23, 2018 , ... Visikol ... Co-Founder Dr. Thomas Villani. Through support from advisors, mentors, the Rutgers Technology Transfer team ... , Visikol’s path from an idea to a successful biotech company has been a ...
Breaking Biology Technology:
(Date:8/29/2018)... ... August 29, 2018 , ... ... first non-invasive technology to identify specific chromosomal abnormalities using morphological assessment through ... Fertility and Australia-based Life Whisperer suggests that artificial intelligence ...
(Date:8/23/2018)... ... ... eight-year-old mini Australian shepherd and a tripod. When Mandy was four years old, she broke ... to repair the leg and each time it was unsuccessful. Once she finally got ... veterinarian, decided to amputate. With only one front leg, mobility in Mandy’s back legs ...
(Date:8/21/2018)... , ... August 20, 2018 , ... ... there are many challenges to consider. Designers must ensure what is designed can ... we will explore some best practices in flow path design with specific focus ...
Breaking Biology News(10 mins):